H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Leap Therapeutics to $5.50 from $7 and keeps a Buy rating on the shares following the Q1 report. For 2024, the firm projectes no revenues and a net loss of $1.53 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPTX:
- Leap Therapeutics Reports First Quarter 2024 Financial Results
- LPTX Earnings this Week: How Will it Perform?
- Leap Therapeutics files to sell 14.18M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Leap Therapeutics to sell 12.66M shares at $2.82 in private placement